Clinical Trial Update: Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating anifrolumab for 24 weeks in patients with Sjögren's syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Sjogren's Syndrome | Phase 2 | Status: UNKNOWN